Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.81 -1.37 (-2.83%)
Streaming Delayed Price Updated: 3:20 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
74 75 Next >
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Bristol-Myers Squibb Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Bristol-Myers Squibb's Earnings Outlook
Via Benzinga
Bristol Myers Squibb Named One of America’s Most JUST Companies by JUST Capital and CNBC
From Bristol Myers Squibb
Via Business Wire
Undervalued Gems: 7 Stocks Set for a Major Rebound
Each of these seven undervalued stocks has fallen by 25% or more from its 52-week high, but may have a path back to prior prices. 
Via InvestorPlace
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
From Bristol Myers Squibb
Via Business Wire
3 Blue Chip Dividend Stocks To Play Defense
We will discuss 3 long-term blue chip stocks to play defense. They have raised their dividends each year for over ten years, have current yields above the S&P 500 Index average, and should continue to... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript
BMY earnings call for the period ending December 31, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Biden Administration To Send Pharma Companies Opening Offers For Medicare Program's First Ever Drug Price Negotiations
The Inflation Reduction Act's impact on drug prices. Medicare challenges pharmaceutical costs, offering relief to seniors and addressing the soaring prices in the U.S. healthcare system. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Stock Market Handles Huge Earnings Week, Fed's Powell, Jobs Report: Weekly Review
The Dow led the major indexes higher. Big techs diverged on results. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
What's Going On With US Pharma Giant Bristol-Myers Squibb Stock Today?
Bristol Myers Squibb reports Q4 revenues of $11.48 billion, up 1% YoY. Eliquis and Opdivo sales drive growth, offsetting Revlimid decline. 
Via Benzinga
Bristol Myers Shares Rise On Fourth-Quarter Earnings Beat
Bristol Myers earnings came in above expectations, although Opdivo sales were slower than expected. BMY stock gained. 
Via Investor's Business Daily
Nasdaq Futures Climb As Meta, Amazon Gains Offset Apple Slide: Analyst Points to 2 Factors Reinforcing Bullish Outlook This Year
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. 
Via Benzinga
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
From Bristol Myers Squibb
Via Business Wire
Earnings Scheduled For February 2, 2024
Companies Reporting Before The Bell • W.W. Grainger (NYSE:GWW) is likely to report quarterly earnings at $8.05 per share on revenue of $4.04 billion. 
Via Benzinga
Investor Optimism Improves Following Earnings, Economic Reports; Dow Jumps Over 350 Points
The CNN Money Fear and Greed index showed an increase in the overall market sentiment, but the index remained in the "Greed" zone on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Amazon, Apple And 3 Stocks To Watch Heading Into Friday
With U.S. stock futures trading mostly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
BMY Stock Dividend Delight: A Blue-Chip’s Healthy Yield
In the grand theater of the financial markets, Bristol-Myers Squibb stands out as a robust performer. Despite the recent pullback, the market sentiment towards this biopharmaceutical titan remains... 
Via Talk Markets
Medicare's Historic Negotiations To Lower Drug Prices, Analysts Anticipate Upto Potential Price Cuts Of 60%
Explore the impact of the U.S. government's proposal on pharmaceuticals! Learn about Medicare's negotiation power, potential price cuts, and industry reactions. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
From Brodsky & Smith LLC
Via GlobeNewswire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
EQNX::TICKER_START (OTCQB:TDSGF),(TSXV:TELO),(NYSE:BMY),(NYSE:TMO),(NASDAQ:NTRA),(NASDAQ:NEO) EQNX::TICKER_END 
Via FinancialNewsMedia
Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high... 
Via Benzinga
Regulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
From Bristol Myers Squibb
Via Business Wire
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
Via Get News
Exposures Product Safety
Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo. 
Via Benzinga
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
--News Direct-- 
Via News Direct
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQ:CRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug... 
Via TheNewswire.com
Exposures Product Safety
Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism?
An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.